Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED)

Affiliations

• ¹ Department of Cardiovascular Medicine, Saga University, Saga, Japan. Electronic address: [email protected].
• ² First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
• ³ Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan.
• ⁴ Department of Internal Medicine, Shirakawa Kosei General Hospital, Shirakawa, Japan.
• ⁵ Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan.
• ⁶ Diabetes Center, Ohta Nishinouchi Hospital, Koriyama, Japan.
• ⁷ Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan.
• ⁸ Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
• ⁹ Department of Regenerative Medicine, Hiroshima University, Hiroshima, Japan.
• ¹⁰ First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
• ¹¹ Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital, Hiroshima, Japan.
• ¹² Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan.
• ¹³ Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
• ¹⁴ Department of Biostatistics, Hyogo Medical University, Nishinomiya, Japan.
• ¹⁵ Department of Regenerative Medicine, Hiroshima University, Hiroshima, Japan.
• ¹⁶ Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan.
• ¹⁷ Department of Cardiovascular Medicine, Saga University, Saga, Japan. Electronic address: [email protected].